current lack of knowledge about whether pharmacological effects are served by the
lipid–protein bilayers or the intra-vesicular contents or both. After browsing the
recent findings in the literature about biodistribution and imaging in Chap. 8, the
readers can now enter into the meditation of the possible use of extracellular
vesicles as therapeutics. How we validate the therapeutic success and how to realize
the therapeutic potential of extracellular vesicles, if any, follow. In Chap. 9, the
readers will meet the similar thoughts and realizations through experiments,
impetuous or meticulous, but based on so much curiosity.
Endogenous nanomedicine was coined by myself to name the entire pursuit to
this direction and endogenous radionanomedicine is the subdiscipline of using
radiolabeled nanomedicines. As was introduced in Chap. 1, endogenous radionanomedicine is using endogenous radionanomedicines, i.e., radiolabeled
endogenous nanomedicines, again, i.e., radiolabeled extracellular vesicles for
therapeutic/ theranostic purposes.
126
Part II: Endogenous Radionanomedicine